P189. National differences in physicians' perspectives of ulcerative colitis experience and management: results from an international survey
S. Schreiber1, J. Panés2, E. Louis3, D. Holley4, 1Department of Medicine I, University Hospital Schleswig-Holstein, Christian Albrechts University, Kiel, Germany, 2Department of Gastroenterology, Hospital Clínic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, 3Department of Gastroenterology, University Hospital of Liège (CHU), Liège University, Liège, Belgium, 4GfK HealthCare, London, United Kingdom
Previous reports from international surveys have shown differences across Canada and 5 European countries in the perspectives of patients with ulcerative colitis (UC) and physicians actively treating UC. Here we report further details on differences across these countries among physicians treating UC regarding perceptions of 5-aminosalicylic acid (5-ASA) therapy and patient adherence.
Physicians were pre-identified from access panels or through custom “phone-to-Web” recruitment. Structured, cross-sectional, online questionnaires were completed by 475 physicians from Canada, France, Germany, Ireland, Spain, and the UK.
Physicians prescribed oral 5-ASA treatment for most of their patients (Ireland [84%], the UK [80%], Spain [79%], Canada [79%], France [62%], and Germany [55%]). Across the countries, ≥85% of physicians were somewhat or very satisfied with the current 5-ASA therapy. However, more physicians in Ireland (47%), Spain (43%; P < 0.05 vs the UK, Germany, and France), and Canada (33%; P < 0.05 vs the UK, Germany, and France) were very satisfied with the current 5-ASAs compared with those in the UK (18%; P < 0.05 vs Germany and France), Germany (7%), and France (7%). Physicians in Spain (54%; P < 0.05 vs the UK, Germany, Canada, and France) were most likely to switch their patients from one oral 5-ASA therapy to another. Physicians in Spain estimated the highest percentage of adherence with 5-ASA therapy (70%; P < 0.05 vs the UK, Germany, and Canada). Physicians in Ireland (73%), Canada (70%; P < 0.05 vs Spain), the UK (65%; P < 0.05 vs Spain), and Germany (61%) believed the main reason patients were not fully adherent with their 5-ASA therapy when in remission was because they felt well; ≥58% of physicians in the UK (P < 0.05 vs Germany and Spain), Canada (P < 0.05 vs Germany and Spain), and France (P < 0.05 vs Germany) attributed patients' non-adherence to forgetting to take medication. Physicians in Canada, the UK, and Germany (P < 0.05 vs Spain and France) believed approximately 30% of patients self-reduced their 5-ASA medication, and ≥60% of physicians in Germany (P < 0.05 vs Spain and France), Canada, the UK, and Ireland estimated that 1%-10% of patients stopped taking their 5-ASA medication during remission.
Results from this analysis suggest that use of 5-ASA, satisfaction with treatment, and estimated adherence vary significantly among physicians from Canada, France, Germany, Ireland, Spain, and the UK.